Galectin Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Galectin Therapeutics

17/05/2021 14:59

* Galectin Therapeutics Inc  GALT.OQ  reported a quarterly
adjusted loss of 11 cents​​ per share for the quarter ended
in March. The lone analyst forecast for the quarter was for a
loss of 17 cents per share.
* Reported revenue was zero​. 
* Galectin Therapeutics Inc's reported EPS for the quarter was a
loss of 11 cents​.
* The mean earnings estimate of analysts was unchanged in the
last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Galectin Therapeutics Inc shares had risen by 94.9% this
quarter and gained 88.8% so far this year.
* The company reported a quarterly loss of $6.34 million.
* Wall Street's median 12-month price target for Galectin
Therapeutics Inc is $14.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 17 at 01:59 p.m. GMT.
​All figures in US dollars